Piramal moves to commercialize amyloid tracer in Korea

The PET amyloid imaging agent florbetaben F-18 may soon be available in South Korea as a result of a licensing agreement and partnership between producer Piramal Imaging and Ci-Co Healthcare, according to a Nov. 21 announcement from Piramal.

Ci-Co, as strategic partner and agent, will be charged with obtaining authorization to commercialize and market the radiotracer from the Korean Health Authorities. Manufacturing and supply are planned with South Korean radiopharmacy network DuChemBio.

"Piramal Imaging is committed to building a global presence in nuclear medicine and making florbetaben F-18 available to patients around the world. Ci-Co Healthcare shares Piramal Imaging's dedication and we look forward to a strong partnership that will allow both companies to achieve its goals," said Piramal board member Ludger Dinkelborg, in a release.